Single-Ascending Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of LY2979165 in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 03 Feb 2017
At a glance
- Drugs MP 101 Mediti Pharma (Primary)
- Indications Bipolar disorders
- Focus Adverse reactions
- 03 Feb 2017 Results of two phase 1 single and multiple dose studies (NCT01248052 and NCT01383967) published in the British Journal of Clinical Pharmacology
- 24 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 11 May 2011 Planned End Date changed from 1 Apr 2011 to 1 May 2011 as reported by ClinicalTrials.gov.